XML 47 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
Nature of Business (Details)
$ in Thousands
6 Months Ended
Jun. 21, 2016
USD ($)
product
Feb. 01, 2016
USD ($)
Jun. 30, 2016
USD ($)
Drug
Jun. 30, 2015
USD ($)
Dec. 31, 2015
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]          
Number of generic drugs | Drug     10    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Proceeds from sale of businesses     $ 437,875 $ 0  
Contingent purchase price from sale of businesses     143,700   $ 0
Impairment     0 3,613  
Discontinued Operations, Disposed of by Sale [Member] | Hemostasis Business [Member]          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Proceeds from sale of businesses   $ 174,100 174,068 $ 0  
Contingent purchase price from sale of businesses   235,000 78,000    
Impairment   133,300      
Goodwill impairment charge   $ 24,500      
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Non-Core ACC Products [Member]          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Proceeds from sale of businesses $ 263,807        
Contingent purchase price from sale of businesses $ 480,000   $ 65,700    
Number of products sold | product 3